Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cortical thickness at the time of the initial attack in two patients with paediatric relapsing-remitting multiple sclerosis.
Fernández-Jaén A, Fernández-Mayoralas DM, Fernández-Perrone AL, Jiménez de la Peña M, Recio Rodríguez M, Calleja-Pérez B, Muñoz Jareño N, Arroyo R, Albert J. Fernández-Jaén A, et al. Among authors: arroyo r. Eur J Paediatr Neurol. 2014 May;18(3):295-300. doi: 10.1016/j.ejpn.2013.12.002. Epub 2013 Dec 24. Eur J Paediatr Neurol. 2014. PMID: 24393840
Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
de Andrés C, Aristimuño C, de Las Heras V, Martínez-Ginés ML, Bartolomé M, Arroyo R, Navarro J, Giménez-Roldán S, Fernández-Cruz E, Sánchez-Ramón S. de Andrés C, et al. Among authors: arroyo r. J Neuroimmunol. 2007 Jan;182(1-2):204-11. doi: 10.1016/j.jneuroim.2006.09.012. Epub 2006 Dec 8. J Neuroimmunol. 2007. PMID: 17157927
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group. Confavreux C, et al. Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23. Lancet Neurol. 2014. PMID: 24461574 Clinical Trial.
Human herpesvirus 6 and multiple sclerosis: a one-year follow-up study.
Alvarez-Lafuente R, De Las Heras V, Bartolomé M, García-Montojo M, Arroyo R. Alvarez-Lafuente R, et al. Among authors: arroyo r. Brain Pathol. 2006 Jan;16(1):20-7. doi: 10.1111/j.1750-3639.2006.tb00558.x. Brain Pathol. 2006. PMID: 16612979 Free PMC article.
Clinical response to interferon-beta-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: a 1-year longitudinal study.
de Andrés C, Aristimuño C, Bartolomé M, de Las Heras V, Martínez-Ginés ML, Arroyo R, Fernández-Cruz E, Sánchez-Ramón S. de Andrés C, et al. Among authors: arroyo r. J Neuroimmunol. 2009 Jul 25;212(1-2):112-20. doi: 10.1016/j.jneuroim.2009.04.009. Epub 2009 May 15. J Neuroimmunol. 2009. PMID: 19446889
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Cohen JA, et al. N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089954 Free article. Clinical Trial.
429 results